Advances in the CDI Treatment Landscape

Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.

Related Videos
Glenn S. Tillotson, PhD: Treating Immunocompromised Patients With RBX2660
Adam Faye, MD: Treating the Older Population With IBD
Related Content

More Epidemiological Monitoring Needed for C Difficile in Chinese Hospitals

June 1st 2023

Magnesium Oxide Supplements Help Treat Patients With Chronic Constipation

May 29th 2023

Vedolizumab Use Increases Risk of CDI Episodes for IBD Patients

May 24th 2023

Sharp Rise in C Difficile Cases Found in Greece During COVID-19 Pandemic

May 23rd 2023

FDA Approves Upadacitinib for Patients With Crohn's Disease

May 18th 2023

Linaclotide Results in Improvements in Functional Constipation for Pediatric Patients

May 11th 2023

More Epidemiological Monitoring Needed for C Difficile in Chinese Hospitals

June 1st 2023

Magnesium Oxide Supplements Help Treat Patients With Chronic Constipation

May 29th 2023

Vedolizumab Use Increases Risk of CDI Episodes for IBD Patients

May 24th 2023

Sharp Rise in C Difficile Cases Found in Greece During COVID-19 Pandemic

May 23rd 2023

FDA Approves Upadacitinib for Patients With Crohn's Disease

May 18th 2023

Linaclotide Results in Improvements in Functional Constipation for Pediatric Patients

May 11th 2023

More Epidemiological Monitoring Needed for C Difficile in Chinese Hospitals

June 1st 2023

Magnesium Oxide Supplements Help Treat Patients With Chronic Constipation

May 29th 2023

Vedolizumab Use Increases Risk of CDI Episodes for IBD Patients

May 24th 2023

Sharp Rise in C Difficile Cases Found in Greece During COVID-19 Pandemic

May 23rd 2023

FDA Approves Upadacitinib for Patients With Crohn's Disease

May 18th 2023

Linaclotide Results in Improvements in Functional Constipation for Pediatric Patients

May 11th 2023
© 2023 MJH Life Sciences

All rights reserved.